Clinical Toxicities of Histone Deacetylase Inhibitors. - Wikidata - awgldk - TriplyDB

Clinical Toxicities of Histone Deacetylase Inhibitors.

Clinical Toxicities of Histone Deacetylase Inhibitors.

http://www.wikidata.org/entity/Q31135325

about

Histone deacetylase signaling in cardioprotection Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia Histone deacetylases in monocyte/macrophage development, activation and metabolism: refining HDAC targets for inflammatory and infectious diseases Small molecule inhibitors of zinc-dependent histone deacetylases Epigenetics in liver disease Epigenetics of Alzheimer's disease and frontotemporal dementia Chemical Inhibition of Histone Deacetylases 1 and 2 Induces Fetal Hemoglobin through Activation of GATA2 A phase I first-in-human study with tefinostat - a monocyte/macrophage targeted histone deacetylase inhibitor - in patients with advanced haematological malignancies.A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer.Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor Comparative pharmacokinetic properties and antitumor activity of the marine HDACi Largazole and Largazole peptide isostere Concomitant histone deacetylase and phosphodiesterase 5 inhibition synergistically prevents the disruption in synaptic plasticity and it reverses cognitive impairment in a mouse model of Alzheimer's disease.Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor.Functional and Transcriptional Characterization of Histone Deacetylase Inhibitor-Mediated Cardiac Adverse Effects in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.Compound 9a, a novel synthetic histone deacetylase inhibitor, protects against septic injury in mice by suppressing MAPK signalling.Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer.Targeting class I histone deacetylases in cancer therapy.Epigenetic-based therapies for Friedreich ataxia.Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.Histone Deacetylase 2 Inhibition Attenuates Downregulation of Hippocampal Plasticity Gene Expression during Aging.Emerging approaches for histone deacetylase inhibitor drug discovery.Anticancer potential of the histone deacetylase inhibitor-like effects of flavones, a subclass of polyphenolic compounds: a review.Histone and Non-Histone Targets of Dietary Deacetylase Inhibitors.Epigenetic research in multiple sclerosis: progress, challenges, and opportunities.Histone deacetylase inhibitors as immunomodulators in cancer therapeutics.Epigenetics in the pathogenesis of RA.A Critical Review of the Evidence Concerning the HIV Latency Reversing Effect of Disulfiram, the Possible Explanations for Its Inability to Reduce the Size of the Latent Reservoir In Vivo, and the Caveats Associated with Its Use in Practice.Histone Deacetylase Inhibitors Prolong Cardiac Repolarization through Transcriptional Mechanisms.Review article: next-generation transformative advances in the pathogenesis and management of autoimmune hepatitis."Neurological complications of new chemotherapy agents".Fetal haemoglobin induction in sickle cell disease.Pharmacological and molecular approaches for the treatment of β-hemoglobin disorders.Epigenetic regulation of motivated behaviors by histone deacetylase inhibitors.Targeted Gene Repression Using Novel Bifunctional Molecules to Harness Endogenous Histone Deacetylation Activity.Identification of potential isoform-selective histone deacetylase inhibitors for cancer therapy: a combined approach of structure-based virtual screening, ADMET prediction and molecular dynamics simulation assay.A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat for pediatric and adult patients and its application for dose specification.Synthesis of Potent and Selective HDAC6 Inhibitors Bearing a Cyclohexane- or Cycloheptane-Annulated 1,5-Benzothiazepine Scaffold.Epigenetic Regulation of Memory-Therapeutic Potential for Disorders.Panobinostat as Pan-deacetylase Inhibitor for the Treatment of Pancreatic Cancer: Recent Progress and Future Prospects.

P2860

Q24568237-52D289A2-BE60-47A4-9AF5-0397FA389C6F Q26767024-886ED642-2664-4D3C-8BB8-3D2B96CE33FA Q26768497-6C186774-D7A2-4B2B-8EB5-97BC46785CB0 Q26824515-10537486-0C88-409B-88B7-E73BF03C1918 Q26849263-CF3DA6EB-9FF9-45D8-9143-DA2AB5A24B43 Q27010153-A4909896-A512-48E9-AED9-E69DA2F0B16F Q28551340-FF2986B3-F5F3-4B1E-8E1F-744288233439 Q33407501-650DEEC6-06D0-4301-8429-6FC7B4DBDBB7 Q33408846-9378809F-F147-416D-81B3-6731835785D5 Q33943388-33907073-E061-4C75-BBEE-1E148E6C340D Q35202369-C38B08CA-118C-43E8-BB27-A4852FC21D5C Q36142843-7E8E70BD-785D-4E53-AD71-126F36EB0BA6 Q36242646-535FADEE-B2CA-49E2-B050-A50DE1B0E957 Q36298507-052779E7-0B72-4169-B661-67BD216F7E78 Q36808601-3FD59087-8296-4206-B5FF-CD7B56602CF9 Q37686141-0E754E91-B243-49F5-9117-51296BE555E4 Q37737611-EF3E0595-766E-4D46-B99B-B73A31FBA603 Q38051736-10141F60-B6B1-4711-BD0E-D10900D894A4 Q38219414-C069EEF0-167A-431E-A007-01B9DB5163D8 Q38240733-4853ED59-548C-4528-B1ED-8E6764A87753 Q38288491-334942A3-5501-481E-98BD-7D443FA6A287 Q38431356-25BEF9A9-F870-4CF0-8CB1-DD159D0E0159 Q38512046-1273F948-B592-405C-B5ED-ABA1117BEC97 Q38572921-5AC79BB4-C7CB-472B-B6F2-B2207739DF17 Q38654321-EDC21B77-F52C-432E-99EC-2E47683110B3 Q38763747-B21E6001-1BC5-4E49-B94E-82AC0B6FEE3F Q39190505-DE3A3F77-9DDC-46A9-ADCE-84C1CBA5EC3A Q39279515-D074484E-D157-43B3-8878-ABF9AB813BDD Q39714637-D591E6FC-BFDD-4687-BD8C-F460813CFC6D Q40044046-76E76812-E4BD-447F-B561-286CF0375A52 Q45069581-B0EE420F-C5D2-4E56-A3AE-35393970A1D1 Q45874514-A879DCE5-F49D-4797-8BBF-FED6C006F169 Q45874809-7BEBD0F7-AED5-4FF8-9BC1-B388894B581C Q47315020-9C2B0B16-DCA0-4729-8075-3203BEDC67D4 Q47599592-B14C8D11-677A-4A87-889D-394BB39C80E7 Q47645910-85DFAD7C-9B6B-4FA4-9335-B5BC4143E09F Q47843990-56412A6A-232A-48E6-A869-5AD3751993EE Q49149016-177C54CB-C675-41AD-ACD5-BD68D6AE7556 Q50588458-E4BE7C07-0B61-49E6-8D5A-79BA1F52798F Q51034578-0980EAC1-7ED5-41C3-ACBD-02B6C50D6422

P2860

Clinical Toxicities of Histone Deacetylase Inhibitors.

http://www.wikidata.org/entity/Q31135325

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Clinical Toxicities of Histone Deacetylase Inhibitors.

@ast

Clinical Toxicities of Histone Deacetylase Inhibitors.

@en

type

label

Clinical Toxicities of Histone Deacetylase Inhibitors.

@ast

Clinical Toxicities of Histone Deacetylase Inhibitors.

@en

prefLabel

Clinical Toxicities of Histone Deacetylase Inhibitors.

@ast

Clinical Toxicities of Histone Deacetylase Inhibitors.

@en

P1433

Q31135325-F6E29B50-ED8A-4646-A3ED-EF80C51D0AB9

P1476

Q31135325-B618543A-25A1-4E2F-AF64-059114ADA5CD

P2093

Q31135325-0606CF21-C4AF-4A20-81A6-5E3B4E5F5414

Q31135325-20745E13-8A28-4585-B723-AE28A7946901

Q31135325-3ABFF4CE-5719-4208-B795-CE920728C633

Q31135325-4C12E27E-F29D-43F6-9628-42D873ED3130

Q31135325-7AB98E81-BB08-49F6-9464-2DE2FBAAF2C6

P2860

Q31135325-05BFF0A6-6854-473B-8DE9-DA26BE9FEAE1

Q31135325-0B8411CB-1346-494D-B4E9-794865E8B769

Q31135325-18FA45B4-8D89-4373-8664-2455F549C742

Q31135325-1C55D629-5945-4224-A0D6-6742079D957D

Q31135325-20B57444-A0EA-4F3B-9344-04FF7A6D5024

Q31135325-26329403-BB15-4F3D-91D1-0A1691387866

Q31135325-26FD3B29-F3EB-4617-AFA2-2829BBC00972

Q31135325-29115847-D7B1-41CD-9743-93E6A9D39C5F

Q31135325-2BB74F31-2381-4900-AF71-BE915EA8BE2E

Q31135325-2F1244D0-0310-41E2-B109-0D495FAA0897

P304

Q31135325-4876D1BC-9612-4FBF-8DC6-444EF2011097

P31

Q31135325-A9DD637E-2A86-4418-BEBE-8456E6BFE584

P356

Q31135325-2BB16627-D2CB-41BA-854C-E73D2287F832

P433

Q31135325-73EE442A-3139-4412-B405-535F059435C4

P478

Q31135325-47E2B10E-F894-415D-AF2A-5EE29E7396A0

P577

Q31135325-A69B84C1-DBCE-45D9-A8B8-99BB7F08F985

P5875

Q31135325-676CAC01-6BA0-476B-91CC-D05BE1F29729

P698

Q31135325-6FA685F4-A4DC-4799-83C2-FE2A9EC053DC

P932

Q31135325-B23790B7-B3C9-4491-A4FE-04524EFD6D90

P356

P1433

Pharmaceuticals

P1476

Clinical Toxicities of Histone Deacetylase Inhibitors.

@en

P2093

Igor Espinoza-Delgado

http://www.w3.org/2001/XMLSchema#string

John J Wright

http://www.w3.org/2001/XMLSchema#string

Richard L Piekarz

http://www.w3.org/2001/XMLSchema#string

Srividya Subramanian

http://www.w3.org/2001/XMLSchema#string

Susan E Bates

http://www.w3.org/2001/XMLSchema#string

P2860

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

Chromatin modifications and their function

Histone Deacetylase Inhibitor Romidepsin Has Differential Activity in Core Binding Factor Acute Myeloid Leukemia

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

Drug-induced prolongation of the QT interval.

Clinical and molecular responses in lung cancer patients receiving Romidepsin.

Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.

A phase I trial of depsipeptide (FR901228) in patients with advanced cancer.

Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.

P304

2751-2767

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3390/PH3092751

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2010-08-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45937534

http://www.w3.org/2001/XMLSchema#string

P698

27713375

http://www.w3.org/2001/XMLSchema#string

P932

4034096

http://www.w3.org/2001/XMLSchema#string